"We're buyers of dips": Mike Wilson, strategist at Morgan Stanley ( MS 1.58%), said he expects a "modest pullback in the ...

This was the stock's second consecutive day of gains.

Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven ...

Amgen (AMGN) to announce Q2 earnings with expected 6% growth in EPS & revenue. Key acquisitions bolster rare disease pipeline ...

Amgen (NASDAQ:AMGN) is set to release its earnings on Tuesday, August 5, 2025. Historically, Amgen's stock has shown a ...

Amgen has notably outpaced the broader market and the healthcare sector in 2025, and analysts remain cautiously optimistic ...

Analysts estimate that Amgen will report an earnings per share (EPS) of $5.26. The announcement from Amgen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

Amgen Inc. (NASDAQ:AMGN) is one of the top cheap pharmaceutical stocks to buy now. Leerink Partners analyst David Risinger ...

This was the stock's third consecutive day of losses.

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

In the latest close session, Amgen (AMGN) was down 1.73% at $301.29. The stock's change was less than the S&P 500's daily ...